Mitsubishi Tanabe to market Aquestive's Exservan in USA

21 January 2021

Japanese drugmaker Mitsubishi Tanabe Pharma (TYO: 4508) and US firm Aquestive Therapeutics (Nasdaq: AQST) have announced a licensing and supply deal for the US rights to commercialize Exservan (riluzole).

This product is an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis (ALS). It was developed by Aquestive using its PharmFilm drug delivery technology.

As a result of the deal, Mitsubishi Tanabe will commercialize Exservan in the USA. It is expected to be available to patients from the middle of 2021. Aquestive will serve as the exclusive sole manufacturer and supplier.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK